BAYN.DE Bayer AG Loading...

From REGN earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
12:30
Jul 30 ◎
Chris Fenimore CFO, Regeneron Pharmaceuticals, Inc. REGN Q2 FY26 call
Bayesian product royalties and profit share contributed a significant increase to other revenue, indicating underlying strength from the Bayer collaboration's portfolio.
BAYN.DE
MED

About BAYN.DE Analyst Coverage

Buzzberg tracks BAYN.DE (Bayer AG) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Past 7 days: 1 watch. Latest voices: Chris Fenimore.